




Hisamitsu Pharmaceutical Co., Inc.

Q3FY02/2008 Results


This presentation material contains information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.

Dec 27th, 2007

Consolidated P/L



Non-consolidated P/L



Core product sales

(Unit: ¥mn)

	Q3 FY2/08	YoY change (%)	FY2/08 Target	Targeted YoY increase
Mohrus tape	49,572	+ 16.4%	62,600	+ 11.4%
(Mohrus Tape L)	18,895	+ 36.7%	23,600	+ 27.0%
Mohrus	10,256	△ 3.2%	13,500	+ 0.1%
Naboal	1,624	+ 6.6%	2,400	+ 18.5%
Inside Pap	900	△ 14.7%	1,200	△ 9.4%
Salonpas	5,401	+ 2.3%	7,100	+ 4.4%
Salonsip	3,452	+ 4.1%	4,000	△ 2.8%
Air-Salonpas	1,570	+ 7.2%	1,600	△ 3.6%
Butenalock	1,571	△ 15.7%	2,500	△ 5.2%
Feitas	3,238	+ 7.3%	5,000	+ 34.7%

Profit and Loss Summary 1 (Unbundling)



Sales
increase

+6,505 (+8.1%)

Rx : Mohrus Tape +6,963, Mohrus Δ 337

OTC: Salonpas+120, Salonsip+137, Air-Salonpas+105

Feitas +220 Butenalock Δ 293


Increase in sales cost **Δ 1,980 (Δ 8.6%)**

Increase in
total profit

+4,526 (+7.9%)

Unit: mn
Figures in parentheses: quarter-to-quarter basis

Profit and Loss Summary 2 (Unbundling)



Unit: mn
 Figures in parentheses: quarter-to-quarter basis

Trend of NSAID market in Japan (Scale by amount)

Unit: mn


	99/08	06/10	07/10	YoY
All nonsteroidal anti-inflammatory drug	245,708	256,683	261,797	+2.0%
Tape preparation	28,708	81,395	91,615	+12.6%
Component ratio	11.7%	31.7%	35.0%	
Gel-patch preparation	79,678	62,780	63,027	+0.4%
Component ratio	32.4%	24.5%	24.1%	
Systemic drug (oral, injection, suppository)	106,807	90,484	89,071	△1.6%
Component ratio	43.5%	35.3%	34.0%	
Other dosage forms (Gel, Cream, etc.)	30,515	22,025	18,084	△17.9%
Component ratio	12.4%	8.6%	6.9%	

Source:IMS JPM


The second generation anti-inflammatory analgesic patches market in Japan (Quantity)



Source:IMS JPM



Domestic market share



Patch and Care of People around the World

Copyright© 2005 Hisamitsu. All right reserved.

Progress of R&D pipelines

R&D pipeline



Stage	R&D Code	Generic Name	Indication	Next Step	Country	Comments
Filed	HFG-512	Fentanyl	Chronnic pain	Approved FY2007	US	Generic product of Duragesic (J&J's product) (Change of product from HFT-290)
Filed	FS-67 (OTC)	L-menthol Salicylate	Shoulder stiffness, myalgia	Approved FY2007	US	Salonpas for which FDA-compliance clinical studies were performed Elastic and soft adhesive plaster
Filed	KPT-220	Ketoprofen	Pain in rheumatoid arthritis	Approved FY2008	J	Additional indication for Mohrus Tape Implementing objective evaluation of pain relief, using pain scoring additional indication Should lengthen life-cycle of this product
preparing for Filing	HFT-290	Fentanyl citrate	Cancer pain	Filed FY2008	J	Once-a-day application Succeeded in development of small, thin patch Will probably replace Janssen's fentanyl tape
Phase 3	NORSPAN	Buprenorphine	Chronic pain	Filed FY2008	J	Once-a-week application Chronic pain in patients who have an inadequate efficacy with NSAIDs
Phase 3	HKT-500	Ketoprofen	Anti-inflammatory analgesic	Filed FY2010	US	Mohrus Tape of US version First attempt of NSAID tape in Rx

- A yellow portion is the part which had change from the Q2(Oct 15th) announcement . .

HFT-290 (Japan, narcotic analgesic, once daily application)

- Phase III study program was ended in October and preparing for Filing
- Application scheduled to be submitted in FY2008

NORSPAN(Japan, Buprenorphine transdermal patch system)

- Phase III study was ended in December 2007
- Application scheduled to be submitted in FY2008 changed from FY2009

HFG-512 (U.S. narcotic analgesic)

- Responding to the instruction given based on FDA's GMP inspection
- Approval anticipated to be granted by the end of FY2007

FS-67 (U.S. OTC Salonpas)

- FDA's GMP inspection completed in November 2006
- Approvable letter was received in December 2006.
Related activities carried out to comply with approval conditions and waiting for FDA's reply.
- Approval anticipated to be granted by the end of FY2007

KPT-220 (Japan, Supplementation of indication of Mohrus Tape for pain in rheumatoid arthritis)

- Application submitted in September
- Approval anticipated to be granted by the end of FY2008

HKT-500 (U.S. Mohrus Tape)

- Re-study started after FDA agreed the protocol for part of the re-study
- Other studies scheduled to orderly start after review and negotiation with FDA

“Improving Quality of Life (QOL) for People in the World”

Dec 27th, 2007